Launch Pad:

Pathways to Cancer InnoVAtion



    November 29th, 2016 | Washington, DC, USA

    As cancer incidence and related healthcare costs continue to grow, we are presented with challenges that will require new ideas, new solutions and renewed focus.


    Veterans are most frequently diagnosed with five cancers: prostate, lung and bronchial, colorectal, urinary and bladder cancers, and skin melanomas. While this is similar to that for Americans as a whole, our service members are disproportionately affected by some, including prostate and lung cancer. To address this, The U.S. Department of Veterans Affairs is calling for collaboration towards national partnership-based solutions for cancer research.


    As an invited partner in the ‘Launch Pad: Pathways to Cancer InnoVAtion’ event, Philips brings strength in connected health technologies and improved access to care through a long-standing, collaborative relationship with the U.S. Military and the VA. We know that protecting the independence and health of our veterans requires overcoming significant challenges, which can’t be solved by one single person or organization.

    Schedule    |    Feature articles    |    Innovations


    Tuesday, November 29th

    Plenary session and innovation showcase



    The latest in the Pathways to InnoVAtion series, the VA Launch Pad brings together internationally renowned oncology experts to participate in a Plenary Session and Innovation Showcase, where research scientists and world-class medical technology specialists will come together to take part in panel discussions and deliver “lightning talks” on relevant oncology topics.


    Launch Pad’s themes include:


    • Revolutionizing screening technology
    • Advancing diagnostics & treatment
    • Improving care coordination
    • Leveraging big data to evaluate patient outcomes. 

    The health of our nation’s Veterans has a profound impact on the health of our society as a whole.

    Successful lung cancer screening starts here


    Lung cancer is a leading cause of cancer death. Low-dose CT screening for lung cancer has shown to detect lung cancer at earlier stages, when its most curable, as well as reduce mortality by 20 percent compared to standard chest x-ray.

    Successful lung cancer screening starts here

    Sharing multiplies knowledge


    Reach better-informed decisions through easy access to patient centric information. Our IntelliSite Pathology solution is a highly scalable platform that enhances productivity with high-resolution digital images, collaboration features, and case management tools.

    Sharing multiplies knowledge


    Let’s build a healthier society

    Learn how Philips is building a healthy society by focusing on where, how and when health happens - from hospital to home, and in everyone’s daily lives.
    Philips holistic approach to health
    Watch video

    What's trending



    Recent tweets

    Read more